Recent Progress in Pharmacogenomics of Antipsychotic Drug Response
- 27 March 2018
- journal article
- review article
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 20 (4) , 24
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Drug-Induced Extrapyramidal SyndromesPsychiatric Clinics of North America, 2016
- The Benefits of Antipsychotic Drugs2016
- Genetic association analysis of N‐methyl‐d‐aspartate receptor subunit geneGRIN2Band clinical response to clozapineHuman Psychopharmacology: Clinical and Experimental, 2016
- Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathwayEuropean Neuropsychopharmacology, 2015
- Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesiaJournal of Psychiatric Research, 2013
- Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight GainArchives of General Psychiatry, 2012
- Antipsychotic drugs and obesityTrends in Molecular Medicine, 2011
- A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trialAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009
- Half a century of antipsychotics and still a central role for dopamine D2 receptorsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
- HLA-B38, DR4, DQw3 and Clozapine-Induced Agranulocytosis in Jewish Patients With SchizophreniaArchives of General Psychiatry, 1990